Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma

David Schiff, Santosh Kesari, John De Groot, Tom Mikkelsen, Jan Drappatz, Thomas Coyle, Lisa Fichtel, Bruce Silver, Ian Walters, David Reardon

Research output: Contribution to journal › Article › peer-review

39 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma'. Together they form a unique fingerprint.

Medicine & Life Sciences